Provided by Tiger Fintech (Singapore) Pte. Ltd.

Minerva Neurosciences

1.54
-0.0800-4.94%
Post-market: 1.540.00000.00%16:08 EDT
Volume:11.22K
Turnover:18.02K
Market Cap:10.77M
PE:8.11
High:1.66
Open:1.62
Low:1.54
Close:1.62
Loading ...

Minerva Neurosciences Reports Improved 2024 Financials

TIPRANKS
·
06 Mar

Minerva Neurosciences Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Feb

Hold Rating for Minerva Neurosciences Amidst Uncertainty Over Roluperidone and Financial Constraints

TIPRANKS
·
26 Feb

Minerva Neurosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Feb

Minerva Neurosciences: Q4 Earnings Snapshot

Associated Press Finance
·
25 Feb

Minerva Neurosciences Q4 2024 GAAP EPS $(0.56) Beats $(1.05) Estimate, Cash, Cash Equivalents And Restricted Cash At December 31, 2024, Were Approximately $21.5M

Benzinga
·
25 Feb

BRIEF-Minerva Neurosciences Q4 Net Income USD -4.272 Million

Reuters
·
25 Feb

Minerva Neurosciences Q4 Income From Operations USD -4.522 Million

THOMSON REUTERS
·
25 Feb

Minerva Neurosciences Q4 Basic EPS USD -0.56

THOMSON REUTERS
·
25 Feb

Minerva Neurosciences Q4 Operating Expenses USD 4.522 Million

THOMSON REUTERS
·
25 Feb

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

GlobeNewswire
·
25 Feb

Minerva Neurosciences Inc expected to post a loss of $1.05 a share - Earnings Preview

Reuters
·
18 Feb

Minerva Neurosciences Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
06 Nov 2024

Minerva Neurosciences: Hold Rating Amid Regulatory Challenges and Uncertain Drug Development

TIPRANKS
·
06 Nov 2024

Minerva Neurosciences Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
06 Nov 2024

Minerva Neurosciences Reports Positive Earnings Amid FDA Challenges

TIPRANKS
·
06 Nov 2024